Literature DB >> 12972939

Molecular disruption of the MRN(95) complex induces radiation sensitivity in head and neck cancer.

Bert W O'Malley1, Daqing Li, James Carney, Joung Rhee, Mohan Suntharalingam.   

Abstract

OBJECTIVES/HYPOTHESIS: The goal of the project was to develop a novel treatment strategy for head and neck cancer that induces radiation sensitivity. We hypothesized that the normal cellular DNA repair response in head and neck squamous cell carcinoma after radiation therapy can be blocked by a dominant negative disruption of the functioning MRN(95) protein complex. To test this hypothesis, we have developed a novel molecular therapy that inhibits the MRN(95) complex in tumor cells. Disruption the MRN(95) complex and thus DNA repair should result in enhanced tumor killing after classic external-beam radiation therapy. STUDY
DESIGN: Experiments with human head and neck squamous cell carcinoma cell lines in vitro were performed.
METHODS: Recombinant adenovirus vectors carrying the genes for enhancing radiation were generated. Human head and neck squamous cell carcinoma cells were treated with recombinant adenovirus vectors carrying the mutated p95 gene (p95-300), which contains the C-terminus 300 amino acids of the Nbs1(p95) protein. Tumor cells were also treated with adenovirus vector carrying full-length p95 protein or DL312 control virus; then all cell lines were subjected to 2 Gy irradiation. Cell growth curves were determined through colorimetric tetrazolium salt assay.
RESULTS: Both the Ad-p95-300 and Ad-p94-his (full-length wild-type gene) demonstrated significant antitumor effect alone and in combination with radiation therapy compared with control samples. Cell cycle analysis demonstrated a shift toward the G2/M phase of the cell cycle. Analysis of telomerase activity demonstrated a significant decrease in telomerase activity after molecular therapy alone, and a greater decrease when combined with radiation therapy.
CONCLUSION: Adenovirus-mediated mutant or full-length p95 molecular therapy demonstrated efficacy for the treatment of head and neck squamous cell carcinoma in vitro. This novel molecular therapy strategy induced significant radiation sensitization, induced a relative G2/M arrest, and decreased telomerase activity, all of which enhance the benefit of radiation therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12972939     DOI: 10.1097/00005537-200309000-00034

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

Review 1.  Developing master keys to brain pathology, cancer and aging from the structural biology of proteins controlling reactive oxygen species and DNA repair.

Authors:  J J P Perry; L Fan; J A Tainer
Journal:  Neuroscience       Date:  2006-12-15       Impact factor: 3.590

2.  Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy.

Authors:  Waleed M Abuzeid; Xiaoling Jiang; Guoli Shi; Hui Wang; David Paulson; Koji Araki; David Jungreis; James Carney; Bert W O'Malley; Daqing Li
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

3.  Molecular disruption of NBS1 with targeted gene delivery enhances chemosensitisation in head and neck cancer.

Authors:  K Araki; T Yamashita; N Reddy; H Wang; W M Abuzeid; K Khan; B W O'Malley; D Li
Journal:  Br J Cancer       Date:  2010-11-09       Impact factor: 7.640

4.  A bioinformatics filtering strategy for identifying radiation response biomarker candidates.

Authors:  Jung Hun Oh; Harry P Wong; Xiaowei Wang; Joseph O Deasy
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

5.  MicroRNA regulation of the MRN complex impacts DNA damage, cellular senescence, and angiogenic signaling.

Authors:  Cristina Espinosa-Diez; RaeAnna Wilson; Namita Chatterjee; Clayton Hudson; Rebecca Ruhl; Christina Hipfinger; Erin Helms; Omar F Khan; Daniel G Anderson; Sudarshan Anand
Journal:  Cell Death Dis       Date:  2018-05-24       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.